Last updated 4/10/23
Summary:
AACR is only a few weeks away - the conferences starts April 14th, also when abstract text is released
What is the most common type of cancer to be presented on this year?
How many companies have similar mechanisms of action?
See our previous BPIQ Pro article HERE for all companies presenting clinical data and which have new data to be presented at AACR. Learn more here about subscribing!
Important Dates for AACR 2023 are Coming Soon!
AACR23 is almost here, with abstract text being released on April 14th, also the first day of the conference. Both late breaking and clinical trial abstract texts will be released on April 14 at 12pm ET. The conference will then begin at 3pm ET on the same day. April 14th is likely to be an important day as the embargo is lifted on data that is included in the abstracts.
Additional press releases from companies can be released when the embargo is lifted which could cause some big stock moves from companies!
See our previous BPIQ Pro article HERE for all companies in clinical trials and which are presenting new data at AACR23.
Key Dates
April 14, 2023: Late-Breaking and Clinical Trials Abstract Texts Posted Online (12 noon ET)
April 14, 2023: AACR Annual Meeting Begins (3:00 p.m. ET)
The most common types of cancer to be presenting at AACR23 by these smid-cap biopharmas include solid tumors, melanomas, and HER2 expressing tumors. Many of these assets are antibodies, CTLA4s, and cell therapies. There is also one personalized cancer vaccine to be presented. See Table 1 for the companies presenting, mechanisms of action, and the tech of the asset.
Table 1. AACR23 smid-cap biopharma presentations, mechanisms of action, type of technology
See our full forum post for which clinical trials are reporting new data at AACR23!
Most common MoA/type of tech:
Antibodies (especially anti-CD, anti-CTLA4, and anti-HER2)
Immunotherapy
Cell therapy
We look forward to April 14th to see what new data is presented by these companies and to see how the market reacts! See even more info on these companies in our BPIQ Pro forum after becoming a subscriber. We are running our End of Q1 Sale until April 4th! Get any Pro Annual subscriptions for 40% Off!
If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.
Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!
See what our members are saying about us:
Mike from United States
“Really loving the site over the competitor... like the layout and speed over the competition...like the individual pages for each drug/treatment”
Carl from United States
“I like your service. I haven’t seen anyone else doing something similar...nothing like this available for retail.”
Essey from Canada
“Love what you’re doing, this website is awesome.”
James from United States
Great site and I see it’s a family run business, great job.”
Comments